Since the report of the first expert panel of the National Cholesterol Education Program in 1988, effectively the first contemporary professional cholesterol guidelines in the United States, lowering of low-density lipoprotein cholesterol (LDL-C) levels has been a cornerstone of atherosclerotic cardiovascular disease (ASCVD) prevention. Consistent with classical and genetic epidemiologic studies implying a causal relationship between LDL-C and ASCVD, multiple randomized clinical trials have consistently observed proportional relationships between LDL-C lowering and ASCVD risk reduction from statins. More recently, these findings have extended to nonstatin LDL-C–lowering medicines, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9)–inhibiting monoclonal antibodies.1-3
Honigberg MC, Natarajan P. Bempedoic Acid for Lowering LDL Cholesterol. JAMA. 2019;322(18):1769–1771. doi:10.1001/jama.2019.16598
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: